This pilot study proposes to perform measurements of approved thoracic impedance technology that will help answer questions in patients with decompensated heart failure.
Improved metrics derived from the transthoracic impedance (Z) available from implanted Medtronic devices may provide more sensitive indicators of the state of compensation for heart failure patients. Quantification of specific data may provide new information that can improve quality of life for patients and offer vital information to clinicians regarding the adequacy of inpatient and outpatient assessment and management of acute decompensated heart failure.
Study Type
OBSERVATIONAL
Enrollment
11
Any Medtronic implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT) device. Device must have capacity to measure thoracic impedance as described in protocol. This includes the majority of FDA-approved Medtronic devices currently in use.
University of Kansas Medical Center
Kansas City, Kansas, United States
Change from sitting to supine to standing in thoracic impedance
thoracic impedance will be measured at each position at baseline visit then again at the follow-up visits through 30 days
Time frame: Baseline, 30 Days
Rate of change in thoracic impedance
Time frame: Baseline, 30 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.